The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 16, 2023

Filed:

Apr. 18, 2017
Applicant:

Baylor College of Medicine, Houston, TX (US);

Inventors:

Stephen M. G. Gottschalk, Houston, TX (US);

Felicia Cao, Houston, TX (US);

Assignee:

Baylor College of Medicine, Houston, TX (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 14/705 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 48/00 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 48/005 (2013.01); A61P 35/00 (2018.01); C07K 14/705 (2013.01); C07K 14/70596 (2013.01); C07K 16/283 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01); Y02A 50/30 (2018.01);
Abstract

Embodiments of the disclosure concern treatment of cancer utilizing methods and compositions that block CD47 such that tumor associated macrophages (TAMs) are not inhibited by CD47 and are able to phagocytose and kill tumor cells. In specific embodiments, the compositions and their use concern fusions of an entity that binds CD47 and an entity that binds cells having FC receptors, such as the FC receptor on TAMs. Certain embodiments concern gene therapy that produces a fusion of the ectodomain of SIRPa and the constant region of IgG4 at a localized tumor or tumor microenvironment, for example. In specific cases, gene transfer is utilized to deliver SIRPa fusion genes into a tumor and/or tumor microenvironment so that the molecules can be expressed locally to increase efficacy (given that the expression of the molecules will be highest at tumor sites) and decrease potential toxicities.


Find Patent Forward Citations

Loading…